Optical purity evaluation and accelerated aging of the new Clareon biomaterial vs other hydrophobic acrylic material in a laboratory setup

Session Details

Session Title: Cataract Surgery Complications: IOL Dislocation and Opacification

Session Date/Time: Tuesday 10/10/2017 | 14:00-16:00

Paper Time: 15:42

Venue: Room 3.6

First Author: : G.Auffarth GERMANY

Co Author(s): :    S. Schickhardt   Q. Wang   H. Fang   F. Hengerer           

Abstract Details

Purpose:

The objective was to determine in an vitro study optical purity of the Intraocular Lens (IOL) material of the Alcon Clareon SY60WF and comparative IOLs (AMO Tecnis PCB00, Bausch & Lomb Envista and Hoya Vivinex XC1) regarding the development of glistenings.

Setting:

David J. Apple International Laboratory for Ocular Pathology, Department of Ophthalmology, University of Heidelberg, Germany

Methods:

The lenses were immersed in a NaCl solution (0,9%) and incubated at 45° for 24 hours in an oven. Afterwards the temperature was reduced to 37° using a water bath. The lenses were stored at 37° for 2.5 hours. After that the lenses were analyzed under a microscope and a dedicated image analysis software was used to count and evaluate glistening formation in the lens material.

Results:

Glistenings formation was quantified in numbers of microvacuoles/mm² (MV/mm²). The glistening formation in the lenses were for the Bausch & Lomb Envista 1.5 ± 0.9 MV/mm², Clareon 4.09 ± 6.67 MV/mm², AMO Tecnis 4.47 ± 5.92 MV/mm² and Hoya Vivinex XC1 6.07 ± 16.72 MV/mm².

Conclusions:

On the so called Miyata scale for clinical glistening grading all lenses were on scale of zero, meaning less then 25 MV/mm². The Clareon SY60WF material can be considered as a glistening free as the Envista IOL from Bausch & Lomb.

Financial Disclosure:

receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, travel has been funded, fully or partially, by a competing company, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives nonNONEmonetary benefits from a competing company., receives nonNONEmonetary benefits from a company producing, developing or supplying the product or procedure presented., receives consulting fees, retainer, or contract payments from a competing company